Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Cellectis S.A.NASDAQ: CLLS

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -467.4%

Operating margin was -467.4% in Q1 FY2026, down 334.3 pp from a year earlier. On a trailing-twelve-month basis it was -67.6%, up 43.4 pp year over year. Over 3 fiscal years it widened by 422.4 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 3 analysts of -285.5% for the fiscal year ending Dec 2026, down from -45.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-467.4%-300.5 pp QoQ
Last fiscal yearDec 2025
-45.3%+98.1 pp YoY
LTMMar 2026
-67.6%+43.4 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-334.3 pp-164.2 pp+170.1 pp
1 year+98.1 pp-240.1 pp-338.3 pp
3 years+422.4 pp-152.2 pp-574.6 pp
5 years-508.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-45.3%
Year-over-year change
+98.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How CLLS compares with its peers on the latest reported figures

  • CLLS's LTM Mar 2026 operating margin of -67.6% is the 2nd highest of the 6 companies compared; the peer median is -2154.0%.
  • Its year-over-year change of +43.4 pp is the highest of 4, against a peer median of -173.6 pp.
  • Over three fiscal years its change of +422.4 pp compares with a peer median of -126.9 pp.
CLLS Competitors Peer median
Operating Margin for CLLS and competitors
Company Period LTM level YoY 3-year change
AMRNAmarin Corporation plcLTM Mar 2026-17.4% +27.0 pp+22.2 pp
CLLSCellectis S.A.LTM Mar 2026-67.6% +43.4 pp+422.4 pp
ACIUAC Immune S.A.LTM Mar 2026-1749.0% -1566.4 pp-126.9 pp
KRROKorro Bio, Inc.LTM Mar 2026-2154.0% -173.6 pp—
MREOMereo BioPharma Group plcLTM Mar 2026-7531.1% ——
SLNSilence Therapeutics plcLTM Mar 2026-9396.6% —-15774.1 pp
DRTSAlpha Tau Medical Ltd.FY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
DBVTDBV Technologies S.A.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding CLLS) -2154.0%-173.6 pp-126.9 pp

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.